Physician profile
Jacob Witt
NPI 1609306737
$1,770.12
in general payments reported to CMS, 2019-2025
24 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $421 · 2024: $1,239 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $260.16 | 2023-2024 | Watchman Flx |
| Philips North America LLC | $245.73 | 2023-2024 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.54 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $158.96 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $112.14 | 2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $79.45 | 2023-2024 | Amvuttra, Onpattro |
| Heartflow, INC. | $76.26 | 2024 | |
| Amgen INC. | $74.99 | 2023-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $66.85 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $59.73 | 2024 | |
| Glaxosmithkline, LLC. | $56.17 | 2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $50.37 | 2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $49.52 | 2024 | Farxiga |
| Lilly USA, LLC | $39.28 | 2024-2025 | Jardiance |
| Pfizer INC. | $35.87 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.59 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.83 | 2023 | Lifevest |
| Merck Sharp & Dohme LLC | $26.81 | 2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $25.41 | 2023 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $25.16 | 2024 | Arcalyst |
| Xeris Pharmaceuticals, INC. | $22.33 | 2023 | Gvoke Hypopen |
| Novo Nordisk INC | $19.15 | 2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $15.35 | 2023 | Rexulti |
| Almatica Pharma LLC | $13.47 | 2024 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.